<DOC>
	<DOC>NCT02431806</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran ER relative to placebo in adolescent outpatients (12-17 years) with Major Depressive Disorder (MDD). In addition, the study is designed to obtain pharmacokinetics (PK) data to guide dose selection for future pediatric studies of levomilnacipran.</brief_summary>
	<brief_title>Safety and Efficacy of Levomilnacipran ER in Adolescent Patients With Major Depressive Disorder</brief_title>
	<detailed_description>Study LVM-MD-11 is a randomized, double-blind, placebo- and active-controlled, parallel group, fixed-dose study in adolescent patients, ages 12-17 years. The study will be approximately 10 weeks in duration: - 1-week screening/washout period - 8-week double-blind treatment period - 1-week double-blind down-taper period Patients who meet the eligibility criteria at Visit 2 (Baseline) will be randomized to 1 of 4 treatment groups: placebo, levomilnacipran 40 mg/day, levomilnacipran 80 mg/day, or fluoxetine 20 mg/day.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Key 1. Male or female outpatients;1217 years of age 2. Meet Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSMIVTR) criteria for Major Depressive Disorder (MDD) , confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for SchoolAge ChildrenPresent and Lifetime (KSADSPL) 3. Score ≥ 40 on the Children's Depression Rating ScaleRevised (CDRSR) at Visits 1 and 2 4. Clinical Global ImpressionsSeverity (CGIS) score ≥ 4 at Visits 1 and 2 5. Reliable caregiver 6. Physical examination, vital signs, clinical laboratory tests, and ECG normal or not clinically significant Key Psychiatric 1. DSMIVTRbased diagnosis of an axis I disorder other than MDD that is the primary focus of treatment 2. Mental retardation or amnestic or other cognitive disorders 3) Significant suicide risk: Suicide attempt within the past year OR Investigator judgment (based on psychiatric interview and CSSRS) Key TreatmentRelated 1. Allergy, intolerance, or hypersensitivity to levomilnacipran, milnacipran, fluoxetine, or any other selective serotonin reuptake inhibitor (SSRI) or serotoninnorepinephrine reuptake inhibitors (SNRI) 2. Use of prohibited concomitant medication that cannot be discontinued Other Key Medical 1. Any current medical condition that might interfere with the conduct of the study, confound the interpretation of study results, or affect patient safety 2. Liver enzyme tests (aspartate aminotransferase) AST and/or alanine aminotransferase (ALT) &gt; 2X the upper limit of normal (ULN) 3. Clinically significant cardiovascular disorders 4. Seizure disorder or risk of seizure 5. Drug or alcohol abuse or dependence (within the past year) 6. Positive urine drug screen or blood alcohol</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>